Topic analysis

Merck's Keytruda: A lifesaving drug, a global divide

An international investigation reveals that Merck's cancer immunotherapy drug Keytruda, while a therapeutic milestone, has created a global health divide due to high prices, extensive patent protections, and varying reimbursement systems. The drug generates billions in sales but remains unaffordable for many patients, particularly in lower-income countries, leading to rationing, lawsuits, and crowdfunding efforts for treatment.